| REC Ref | | | | Date of First Patient Recruited | Duration between Date Site Selected and Date Site Confirmed | _ | between Date Site Selected and First Patient Recruited | Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Confirmed | | Start | Reasons for Delay | Reasons for delay correspon d to: |
|------------|--------|--|-----|--|---|-------|--|------------|-----------------------|-------------------------|--------------------------------------|------------|---|------------|-------------------------------|--|
| 17/LO/0584 | | A mechanistic non-invasive imaging study of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography | Yes | 29/03/2019 | ' ' | 108 | 109 | 04/10/2018 | 10/12/2018 | 07/12/2018 | 3 11/12/2018 | 11/12/2018 | | 11/12/2018 | G - No patients consented | Neither |
| 18/YH/0127 | 239022 | | Yes | 15/12/2018 | 3 26 | 5 33 | 59 | 09/03/2018 | 17/10/2018 | 3 21/05/2018 | 3 12/11/2018 | 12/11/2018 | | 06/12/2018 | | |
| 17/LO/0389 | 221666 | Psilocybin for major depression: A randomized control trial | Yes | 22/01/2019 | 79 | 82 | 161 | 18/07/2018 | 14/08/2018 | 3 18/06/2018 | 26/10/2018 | 01/11/2018 | 3 | 01/11/2018 | D - Sponsor Delays | Sponsor |
| | | | | | | | | | | | - | | | | E - Staff availability issues | |
| 18/LO/0761 | | A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs) | Yes | 20/02/2019 | 35 | 5 15 | 5 50 | 01/11/2018 | 01/01/2019 | 9 24/01/2019 | 30/01/2018 | 05/02/2019 | | 05/02/2019 | F - No patients seen | |
| 17/SC/0090 | 215068 | A trial using ctDNA blood tests to detect cancer cells after standard treatment to trigger additional treatment in early stage triple negative breast cancer patients (c-TRAK-TN) | No | | 195 | 5 | | 23/06/2017 | 31/07/2018 | 8 05/07/2017 | 7 | 11/02/2019 | | 03/05/2019 | C - Closed by sponsor | Sponsor |
| | | | | | | | | | | | | | | | H - Contracting delays | |
| 18/LO/1063 | | The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebocontrolled, Phase 3b study-Actellion - AC-065A308 | Yes | 14/11/2018 | 38 | 3 40 | 78 | 16/10/2017 | 28/08/2018 | 12/07/2018 | 3 29/08/2018 | 05/10/2018 | | | G - No patients consented | Neither |
| 18/LO/1186 | | Atrial Fibrillation (PRESTIGE-AF) | Yes | 14/05/2019 | | | | | | 07/12/2018 | | | | 09/05/2019 | D - Sponsor Delays | Sponsor |
| 17/LO/1660 | | | Yes | 05/10/2018 | + | _ | | | | 3 22/11/2017 | | | | ļ | | |
| 18/LO/0745 | | . , , | Yes | 21/12/2018 | 1 | 1 | 78 | | | 3 11/07/2018 | | | | 05/11/2018 | | Neither |
| 18/EE/0005 | | A MULTICENTER, OPEN-LABEL STUDY TO ESTIMATE THE EFFECT SIZES OF HRCT ENDPOINTS IN RESPONSE TO GLUCOCORTICOID INDUCTION THERAPY IN SUBJECTS WITH PULMONARY SARCOIDOSIS | No | | 104 | | | | | 19/07/2018 | | 31/10/2018 | | | D - Sponsor Delays | Sponsor |
| 18/LO/0779 | | A Randomized (1:1), Double blind, Multi center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF 0444913) or Azacitidine With or Without Glasdegib in Patients With Previously Untreated Acute Myeloid Leukemia. | Yes | 25/04/2019 | 163 | 3 133 | 3 296 | 18/12/2017 | 03/07/2018 | 15/06/2018 | 3 03/07/2018 | 13/12/2018 | | 07/03/2019 | D - Sponsor Delays | Sponsor |
| | | | | | | | | | | | | | | | I - Rare diseases | |
| 18/WS/0087 | | Optimal duration of Cooling therapy in Mild Encephalopathy (COMET 1) | Yes | 15/10/2018 | 7 | 70 | 77 | 02/05/2018 | 30/07/2018 | 18/06/2018 | 3 06/08/2018 | 06/08/2018 | | 06/08/2018 | F - No patients seen | Neither |
| 18/YH/0212 | 237279 | | Yes | 13/02/2019 |) 5 | 5 72 | 2 77 | 14/08/2018 | 28/11/2018 | 3 14/08/2018 | 3 28/11/2018 | 03/12/2018 | ; | 10/12/2018 | G - No patients consented | Neither |
| 18/LO/0170 | 236855 | | Yes | 01/02/2019 | 89 | 9 45 | 134 | 29/01/2018 | 20/09/2018 | 8 04/04/2018 | 11/12/2018 | 18/12/2018 | | 18/12/2018 | D - Sponsor Delays | Sponsor |
| | | | | | | | | | | | | | | | G - No patients consented | |
| 18/EE/0091 | | A first in human, phase 1 safety study in two parts to determine the safety, tolerability and anti-cancer immuno-modulatory effects of MRx0518 in patients with solid tumours awaiting surgical removal of the tumour. | No | | 97 | 7 | | 04/05/2018 | 14/11/2018 | 3 06/06/2018 | 3 | 19/02/2019 | | 26/03/2019 | D - Sponsor Delays | Sponsor |
| | | | | | | | | | | | | | | | F - No patients seen | |
| 19/LO/0138 | | Effect of EVOlocumab on CARotid plaque composition in asymptomatic carotid artery stenosis (EVOCAR-1) | No | | 75 | 5 | | 30/10/2018 | 27/03/2019 | 06/03/2019 | 20/12/2018 | 10/06/2019 | | | F - No patients seen | Sponsor |

| 18/LO/1162 | 242411 A Study to Evaluate the Safety and Efficacy of Staged Bilateral | Yes 17/0 | 1/2019 | 35 | 41 | 76 | 25/04/2018 | 02/11/2018 | 17/10/2018 | 07/12/2018 | 07/12/2018 | | G - No patients consented | Neither |
|------------|--|----------|--------|-----|-----|-----|------------|--------------|--------------|------------|------------|------------|-----------------------------------|----------|
| 10/10/1102 | ExAblate Treatment of Medication Refractory Bilateral Essential Tremor | 17,0 | 1,2013 | 33 | 1 | 70 | 23/04/2010 | 02/11/2010 | 7771072010 | 07/12/2010 | 0771272010 | | d No patients consented | Neither |
| 18/EM/0153 | 240773 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency | No | | 38 | | | 16/05/2018 | 31/08/2018 | 3 28/08/2018 | 24/09/2018 | 08/10/2018 | | F - No patients seen | Neither |
| | | | | | | | | | | | | | G - No patients consented | |
| 18/LO/0235 | 240315 An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials | No | | 60 | | | 28/02/2018 | 17/12/2018 | 3 17/04/2018 | | 15/02/2019 | | D - Sponsor Delays | Neither |
| | | | | | | | | | | | | | J - Other | |
| 18/NW/0109 | 234734 PHIL evaluation in the endovascular treatment of intracranial dural AVF | Yes 07/0 | 5/2019 | 30 | 207 | 237 | 26/02/2018 | 12/09/2018 | 14/05/2018 | 12/09/2018 | 12/10/2018 | | F - No patients seen | Neither |
| 18/LO/0393 | 240955 A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects with Severe Haemophilia B | No | | 51 | | | 15/03/2018 | 25/07/2018 | 20/06/2018 | 04/07/2018 | 14/09/2018 | | C - Closed by sponsor | Sponsor |
| | | | | | | | | | | | | | D - Sponsor Delays | |
| 18/LO/0919 | 235977 A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation | Yes 08/0 | 5/2019 | 39 | 159 | 198 | 11/04/2018 | 22/10/2018 | 29/08/2018 | 19/11/2018 | 30/11/2018 | 07/01/2019 | E - Staff availability issues | Neither |
| | | | | | | | | | 1 | | | | F - No patients seen | |
| 16/SS/0070 | 202282 PREvention of Complications to Improve Outcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment. | No | | 113 | | | 12/07/2018 | 04/02/2019 | 05/06/2017 | 01/05/2019 | 28/05/2019 | | D - Sponsor Delays | Sponsor |
| 18/LO/0719 | 235423 A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G) | No | | 3 | | | 19/10/2017 | 29/10/2018 | 3 10/07/2018 | 17/10/2018 | 01/11/2018 | 05/11/2018 | I - Rare diseases | Neither |
| 18/SC/0392 | 244109 Phase 2 Multicenter, Double-Blind, Dose Finding, Placebo Controlled, Safety, Efficacy and Pharmacokinetic Study of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH) | No | | 224 | | | 21/09/2018 | 21/09/2018 | 19/10/2018 | 09/04/2019 | 03/05/2019 | 06/06/2019 | D - Sponsor Delays | Sponsor |
| 18/LO/1461 | 245412 A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) | Yes 12/0 | 6/2019 | 120 | 103 | 223 | 06/04/2018 | 01/11/2018 | 19/10/2018 | 27/02/2019 | 01/03/2019 | | D - Sponsor Delays | Sponsor |
| | | | | | | | | ļ., | <u> </u> | | | | G - No patients consented | |
| 18/YH/0014 | 224065 External frame versus internal locking plate for articular pilon fracture fixation: a multi-centre randomised controlled trial | Yes 25/0 | 2/2019 | 89 | 49 | 138 | 10/10/2018 | 10/10/2018 | 13/02/2018 | | 07/01/2019 | | D - Sponsor Delays | Sponsor |
| | | | | | | | | | | | | | H - Contracting delays | |
| 18/LO/1338 | Radiological Approaches including MRI and ultrasound | | 0/2018 | 12 | 27 | | | | 10/09/2018 | | | 10/10/2018 | | |
| 18/YH/0099 | 241430 A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD) | Yes 01/0 | 9/2018 | 1 | 22 | 23 | 29/05/2018 | 09/08/2018 | 3 23/04/2018 | | 10/08/2018 | 14/08/2018 | I - Rare diseases | Neither |
| 18/LO/1525 | 240039 Assessment of the Impact of Real-time Continuous Glucose Monitoring on People Presenting with Severe Hypoglycaemia (AIR-CGM) | Yes 03/0 | 1/2019 | 59 | 48 | 107 | 31/07/2018 | 18/09/2018 | 09/11/2018 | 28/08/2018 | 16/11/2018 | | A - Permissions delayed/denied | Sponsor |
| | | | | | | | <u></u> | | | | | | D - Sponsor Delays | <u> </u> |
| 18/NE/0281 | 237312 Neuromuscular Electrical Stimulation(NMES) for the treatment of Diabetic Peripheral Neuropathy. A Randomised Controlled Trial | Yes 19/0 | 2/2019 | 0 | 0 | 0 | | 19/02/2019 | 23/10/2018 | | 19/02/2019 | | | |
| 18/LO/0430 | 241907 An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura | Yes 01/0 | 2/2019 | 28 | 29 | 57 | 02/03/2018 | 8 06/12/2018 | 11/06/2018 | | 03/01/2019 | 03/01/2019 | I - Rare diseases | Neither |

| 18/LO/1187 | 240011 (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib | No | | 197 | | 13/04 | 1/2018 25/ | /07/2018 | | 24/04/2018 | 07/02/2019 | 11/02/2019 | D - Sponsor Delays | Sponsor |
|------------|--|-----|------------|-----|-----|-----------|------------------|----------|------------|------------|--|------------|-------------------------------|------------|
| | and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy) | | | | | | | | | | | | | |
| | | | | | | | | | | | | | G - No patients consented | |
| 18/SW/0039 | 229163 Induction of labour for predicted macrosomia | No | | 14 | | 29/06 | 5/2018 03/ | /10/2018 | 20/03/2018 | 17/10/2018 | 17/10/2018 | 04/12/2018 | G - No patients consented | Neither |
| 18/EM/0112 | cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic | Yes | 22/11/2018 | 45 | 98 | 143 20/06 | 5/2018 02/ | /07/2018 | 12/06/2018 | 13/08/2018 | 16/08/2018 | 17/09/2018 | D - Sponsor Delays | Sponsor |
| | leukaemia (ALL) in complete remission | - | + | | | | | | | | | | I. Dana d'arrana | + |
| 18/LO/0866 | 224730 Pevention of hypertensive injury to the brain by intensive treatment after intracerebral haemorrhage: a pilot randomised trial of home telemetry-guided treatment | Yes | 09/05/2019 | 18 | 52 | 70 13/07 | 7/2018 28/ | /02/2019 | | 11/03/2019 | 18/03/2019 | 18/03/2019 | I - Rare diseases | |
| 17/SS/0105 | 209066 Multicentre, prospective randomized open label, blinded- endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischaemic stroke with proven acute symptomatic occlusion | No | | 152 | | 15/06 | 5/2018 27/ | /09/2018 | 27/04/2018 | | 26/02/2019 | | D - Sponsor Delays | Sponsor |
| | acute symptomatic occiusion | | | | | | | | | | | | J - Other | + |
| 18/LO/1215 | 245798 A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 – TRial of erYaspase in pancreatic CAncer | No | | | | 06/07 | 7/2018 31/ | /07/2018 | 22/08/2018 | 06/07/2018 | | 29/03/2019 | J - Other | Neither |
| 17/LO/1018 | 224051 An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies | Yes | 31/12/2018 | 72 | 18 | 90 01/08 | 3/2018 02/ | /10/2018 | 06/09/2018 | | 13/12/2018 | 19/12/2018 | D - Sponsor Delays | Sponsor |
| | | | | | | | | | | | | | H - Contracting delays | |
| 18/LO/0330 | 236942 A pragmatic, multi-centre, three-armed randomised controlled trial to assess the clinical effectiveness and safety of time lapse imaging in in-vitro fertilisation treatment | Yes | 03/05/2019 | 30 | 225 | 255 31/07 | 7/2018 21/ | /08/2018 | 25/05/2018 | 20/09/2018 | 20/09/2018 | 03/04/2019 | E - Staff availability issues | NHS Provid |
| 18/EE/0260 | 230833 BN40031- CREAD Open Label Extension Study | Yes | 27/11/2018 | 55 | 6 | 61 18/09 | /2017 27/ | /09/2018 | | 21/11/2018 | 21/11/2018 | 22/11/2018 | D - Sponsor Delays | Sponsor |
| 17/WM/0117 | 7 223480 Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity | No | | 119 | | 10/07 | 7/2018 12/ | /12/2018 | | | 10/04/2019 | | D - Sponsor Delays | Sponsor |
| 18/LO/1709 | 244863 PRIME-HCC: Preliminary assessment of safety and bioactivity of the Ipilimumab and Nivolumab combination prior to liver resection (LR) in hepatocellular carcinoma (HCC) | No | | 13 | | | 25/ | /01/2019 | | 25/01/2019 | 07/02/2019 | 01/03/2019 | H - Contracting delays | Neither |
| 16/LO/1567 | | Yes | 13/02/2019 | 110 | 14 | 124 16/01 | /2018 12/ | /10/2018 | | 09/02/2018 | 30/01/2019 | 11/02/2019 | D - Sponsor Delays | Sponsor |
| | | | + + | | | 1 | | | | | | | H - Contracting delays | + |
| 18/SW/0219 | 250410 A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AG-348 IN ADULT SUBJECTS WITH NON- TRANSFUSION-DEPENDENT THALASSEMIA-AG348-C-010 | Yes | 01/05/2019 | 22 | 96 | 118 29/08 | 8/2018 03/ | /01/2019 | 20/11/2018 | | 25/01/2019 | | F - No patients seen | Neither |
| | TIMANSI OSION-DEPENDENT THALASSENIA-AGS46-C-010 | - | + + | + | | | - - | | | | | | I - Rare diseases | + |
| 18/YH/0136 | 214921 A Multi-Centre, Pilot, Prospective, Clinical Investigation of DermaRep™ Device in the treatment of Venous Leg Ulcers. | Yes | 14/02/2019 | 97 | 14 | 111 21/09 |)/2018 26/ | /10/2018 | 20/08/2018 | | 31/01/2019 | 01/02/2019 | D - Sponsor Delays | Sponsor |
| | Definancy Device in the treatment of Venous Leg Orders. | | + | + | | | - - | | | | | | H - Contracting delays | + |
| 17/NE/0061 | 215780 Colchicine for Prevention of Vascular Inflammation in Non- Cardioembolic Stroke - A Randomised Clinical Trial of Low-Dose Colchicine for Secondary Prevention After Stroke | Yes | 16/04/2019 | 13 | 43 | 56 08/02 | 2/2018 19/ | /02/2019 | 25/07/2017 | 06/02/2019 | 04/03/2019 | | John delang delays | |

| 10/EN//02E6 | 249467 Dandamized Double Blind Blacehe Centrolled Barallel Croun | No | т т | | | 20/09/2019 | 26/11/2019 | <u> </u> | 1 | Ι Ι | | D. Chancar Dalays | Cnoncor |
|-------------|---|-----|------------|-----|-----|----------------|------------|--------------|------------|------------|------------|---------------------------|---------|
| 18/EM/0256 | 248467 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction | No | | | | 30/08/2018 | 26/11/2018 | 5 | | | | D - Sponsor Delays | Sponsor |
| | | | | | | | | | | | | J - Other | |
| 18/EE/0300 | 236285 PROMPT: Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer | No | | 113 | | 26/10/2018 | 08/11/2018 | 19/10/2018 | | 01/03/2019 | 01/04/2019 | D - Sponsor Delays | Sponsor |
| 18/SO/0384 | 245537 A Phase I/IIa Sporozoite Challenge Study to assess the safety, immunogenicity and protective efficacy of intravenous boosting with malaria vaccine candidates ChAd63 and MVA encoding METRAP | Yes | 15/12/2018 | 26 | 12 | 38 07/11/2018 | 07/11/2018 | 01/11/2018 | 30/11/2018 | 03/12/2018 | 03/12/2018 | | |
| 18/SC/0591 | 250421 A Randomized, Open Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor of High Tumor Mutational Burden (TMB-H) | Yes | 09/04/2019 | 106 | 32 | 138 08/06/2018 | 22/11/2018 | 3 24/01/2019 | 27/07/2018 | 08/03/2019 | 13/03/2019 | D - Sponsor Delays | Sponsor |
| 18/EM/0280 | 245964 A FIRST IN HUMAN MULTI-CENTER, OPEN LABEL, PROSPECTIVE STUDY TO EVALUATE THE SAFETY, USABILITY AND PERFORMANCE OF THE V-LAP SYSTEM | No | | 37 | | 05/12/2018 | 28/01/2019 | 27/01/2019 | 20/02/2019 | 06/03/2019 | | | |
| 18/LO/1176 | 234823 PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE | No | | 70 | | 09/04/2018 | 11/07/2018 | 21/08/2018 | | 19/09/2018 | | D - Sponsor Delays | Sponsor |
| 19/LO/0083 | 201045 Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study) | No | | | | 07/12/2018 | 11/03/2019 | 15/02/2019 | 07/12/2018 | | 01/04/2019 | | |
| 18/LO/1549 | 247067 A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of Unknown primary - CUPem | Yes | 28/02/2019 | 21 | 24 | 45 | 14/01/2019 | 15/11/2018 | | 04/02/2019 | 22/02/2019 | G - No patients consented | Neither |
| 18/EM/0245 | 242737 Phase I study of High Intensity Focused Ultrasound (HIFU) in Early Rectal Cancer | No | | 35 | | 28/08/2018 | 16/11/2018 | 01/11/2018 | | 21/12/2018 | | G - No patients consented | Neither |
| 16/EM/0322 | 202096 Tenecteplase in Wake-up Ischaemic Stroke Trial | No | | 28 | | 14/03/2018 | 10/12/2018 | 18/08/2017 | 21/11/2018 | 07/01/2019 | 21/01/2019 | G - No patients consented | Neither |
| 18/LO/0518 | 237346 A phase 2/3, multicentre, open-label, multi-cohort, two-part study evaluating the pharmacokinetics, safety and efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) administered with a background regimen in HIV-1 infected, treatment experienced, virologically suppressed paediatric subjects | 1 | | 112 | | | _ | 3 25/07/2018 | | | | H - Contracting delays | Sponsor |
| 18/LO/1203 | 242451 ORBITA-2: A placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina (Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina 2) | 1 | 08/02/2019 | 11 | 7 | 18 11/07/2018 | 21/01/2019 | 31/08/2018 | | 01/02/2019 | | | |
| 18/NE/0142 | 242919 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis | Yes | 11/12/2018 | 113 | 35 | 148 04/05/2018 | 16/07/2018 | 13/07/2018 | 01/11/2018 | 06/11/2018 | | D - Sponsor Delays | Sponsor |
| 18/LO/1317 | 250312 Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study | Yes | 26/10/2018 | 11 | 10 | 21 03/07/2018 | 05/10/2018 | 20/08/2018 | 16/10/2018 | 16/10/2018 | 22/10/2018 | | |
| 18/NI/0129 | 218623 Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients. | Yes | 18/03/2019 | 19 | 104 | 123 03/07/2018 | 15/11/2018 | 17/10/2018 | 20/11/2018 | 04/12/2018 | | F - No patients seen | Neither |
| 18/LO/1400 | 250545 A prospective study to assess the efficacy and safety of the BlueWind RENOVA iStim™ system for the treatment of patients diagnosed with overactive bladder | No | | | | 18/07/2018 | 11/10/2018 | 3 | | | | D - Sponsor Delays | Sponsor |
| 17/LO/0182 | 213821 A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT™ G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures | Yes | 28/11/2018 | 4 | 23 | 27 07/08/2018 | 01/11/2018 | 30/03/2017 | 01/11/2018 | 05/11/2018 | | | |

| 18/WA/0161 | 238902 An open-label, multi-centre, randomised, switch study to evaluate | No | | 92 | | 10/09/2018 | 10/09/2018 | | 10/09/2018 | 11/12/2018 | 18/12/2018 | A - Permissions | Neither |
|-------------|--|-----|------------|-----|----|----------------|------------|------------|------------|------------|------------|-------------------------------|---------|
| | the virological efficacy over 96 weeks of 2-drug therapy with DTG+RPV FDC in antiretroviral treatment-experienced HIV-1 infected subjects virologically suppressed with NNRTIs resistance mutation K103N. | | | | | | | | | | | delayed/denied | |
| | | | | | | | | | | | | D - Sponsor Delays | |
| | | | | | | | | | | | | E - Staff availability issues | |
| 18/SC/0242 | 238151 A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients. | Yes | 12/02/2019 | 115 | 15 | 130 03/10/2018 | 05/10/2018 | 23/08/2018 | | 28/01/2019 | | H - Contracting delays | Sponsor |
| 18/EM/0311 | 254008 A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Disease (COPD) | | 10/01/2019 | 6 | 21 | 27 11/10/2018 | 14/12/2018 | 14/12/2018 | | 20/12/2018 | 20/12/2018 | | |
| 19/LO/0067 | 256498 The effect of cross-linked sodium hyaluronate on the quality of optical coherence tomography imaging | Yes | 20/06/2019 | 28 | 69 | 97 11/12/2018 | 15/03/2019 | | 15/03/2019 | 12/04/2019 | 12/04/2019 | | |
| 18/WA/0239 | 243333 Delivering the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis | No | | 11 | | 05/12/2018 | 28/01/2019 | 21/12/2018 | | 08/02/2019 | 02/01/2019 | | |
| 19/HRA/0634 | 258886 Mobile learning resources as a tool for improving clinician's ability to break bad news: A quasi-randomised controlled trial | Yes | 24/02/2019 | 9 | 16 | 25 28/01/2019 | 30/01/2019 | 28/01/2019 | 08/02/2019 | 08/02/2019 | | | |
| 19/LO/0282 | | No | | 14 | | | 12/03/2019 | 12/03/2019 | | 26/03/2019 | | | |
| 18/EE/0099 | 239606 An open label, randomised, phase III Study cOmparing trifLuridine/tipiracil (\$ 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study) | No | | 40 | | 13/10/2017 | 15/02/2019 | 01/06/2018 | 08/12/2017 | 27/03/2019 | 28/03/2019 | | |
| 17/LO/1921 | 236323 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION | | | | | 23/01/2019 | 07/02/2019 | 11/12/2018 | | | | | |
| 19/SW/0028 | 255759 A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No | | | | 05/11/2018 | 25/02/2019 | | | | | | |
| 19/LO/0150 | 258058 A double-blind, placebo-controlled, randomised phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut-allergic young children 1-3 years of age | Yes | 18/06/2019 | 36 | 14 | 50 11/10/2018 | 29/04/2019 | 11/03/2019 | 03/05/2019 | 04/06/2019 | 04/06/2019 | | |
| 18/LO/0324 | 220073 The VIDEO Trial:A Feasibility Randomised Control Trial of Vitrectomy Plus Standard Care Intravitreal Ranibizumab Injections versus Standard Care Intravitreal Ranibizumab injections Alone In Patients With Centre Involving Diabetic Macular Edema | No | | 24 | | 16/08/2018 | 19/02/2019 | | | 15/03/2019 | | | |
| 16/EM/0186 | 173279 Can we save the rectum, by watchful waiting ortransanal surgery following (chemo)radiotherapy | No | | | | | 04/04/2019 | 31/10/2016 | | | | | |
| 17/LO/1875 | An international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse | No | | | | 26/09/2018 | 30/10/2018 | 08/01/2018 | | | | | |
| 17/LO/0232 | An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations | No | | 2 | | 30/10/2018 | 15/04/2019 | | 04/04/2019 | 17/04/2019 | 10/06/2019 | | |
| 17/NE/0090 | 203556 International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia | No | | | | 18/04/2019 | 23/04/2019 | | | | | | |

| | | | | | | | | | | | | | 1 |
|--------------|--|-----|------------|-----|----|-------------|----------------|---------------|------------|------------|--------------|----------------------|---------|
| 17/SW/0250 | 222991 Conventional versus Minimally Invasive extra-corporeal | No | | | | 03/05/20 | 19/06/201 | 9 02/11/2017 | ' | | | | |
| | circulation in patients undergoing Cardiac Surgery: a randomised | | | | | | | | | | | | |
| | controlled trial (COMICS) | | | | | | | | | | | | |
| 18/EE/0378 | , | No | | 36 | | 18/04/20 | 19 23/05/201 | 9 10/01/2019 | | 28/06/2019 | | | |
| | to Evaluate the Efficacy and Safety of Conbercept Intravitreal | | | | | | | | | | | | |
| | Injection in Subjects with Neovascular Age-related Macular | | | | | | | | | | | | |
| | Degeneration | | | | | | | | | | | | |
| 18/EE/0390 | 253601 SELECT - A multicenter, randomized, double-blind, placebo- | No | | | | 05/02/20 | 19 31/05/201 | 9 25/03/2019 | | | | | |
| | controlled, parallel-group, group-sequential, adaptive, Phase 3 | | | | | | | | | | | | |
| | study with open-label extension period to assess the efficacy and | | | | | | | | | | | | |
| | safety of selexipag as an add-on to standard of care therapy in | | | | | | | | | | | | |
| | subjects with inoperable or persistent/recurrent after surgical | | | | | | | | | | | | |
| | treatment Chronic Thromboembolic Pulmonary Hypertension. | | | | | | | | | | | | |
| 18/LO/0555 | | No | | 12 | | | 03/05/201 | 9 19/04/2018 | 15/05/2019 | 15/05/2019 | 05/05/2019 | | |
| 10, 20, 0000 | late Ovarian Removal | | | | | | 03,03,202 | 3 13,0 1,2010 | 13,03,2013 | 13,03,2013 | 03/03/2023 | | |
| 18/LO/0900 | 154432 WithHolding Enteral feeds Around packed red cell Transfusion to | Voc | 13/11/2018 | 23 | 41 | 64 25/04/20 | 19 10/09/201 | 9 06/07/2019 | 02/10/2019 | 03/10/2018 | 12/11/2018 | , | |
| 18/10/0900 | prevent necrotising enterocolitis in preterm neonates: a multi- | 163 | 13/11/2018 | 23 | 41 | 04 23/04/20 | 10/03/201 | 8 00/0//2018 | 03/10/2016 | 03/10/2018 | 12/11/2018 | | |
| | · · | | | | | | | | | | | | |
| | centre, electronic patient record (EPR), randomised controlled | | | | | | | | | | | | |
| 40/10/4022 | point-of-care pilot trial | NI- | + | | | 05/02/20 | 10 20 /05 /204 | 0 44/05/2040 | 06/02/2046 | | | | |
| 18/LO/1022 | | No | | | | 06/02/20 | 19 29/05/201 | 9 14/05/2019 | 06/02/2019 | ' | | | |
| | with Nivolumab +/- Ipilimumab to augment response in | | | | | | | | | | | | |
| | homologous repair deficient patients with relapsed Ovarian, | | | | | | | | | | | | |
| | primary peritoneal and fallopian tube cancer | | | | | 22/11/22 | | | | | | | |
| 18/LO/1258 | 248312 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate | No | | | | 02/11/20 | 12/11/201 | 8 | | | | | |
| | the Efficacy and Safety of BG00011 in Patients With Idiopathic | | | | | | | | | | | | |
| | Pulmonary Fibrosis | | | | | | | | | | | | |
| 18/LO/1588 | 248946 A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with | No | | 2 | | 15/06/20 | 18 03/04/201 | 9 05/11/2018 | 13/03/2019 | 05/04/2019 | 10/04/2019 | | |
| | Platinum Doublet Chemotherapy and Radiotherapy for | | | | | | | | | | | | |
| | Participants with Unresectable, Locally Advanced Stage III Non- | | | | | | | | | | | | |
| | Small Cell Lung Cancer (NSCLC) | | | | | | | | | | | | |
| 18/LO/1629 | 214262 A prospective study of tolerance comparing the current hydration | Yes | 25/03/2019 | 34 | 82 | 116 | 29/11/201 | 8 13/12/2018 | s | 02/01/2019 | 02/01/2019 | F - No patients seen | Neither |
| | regimen for the ABC02 chemotherapy regimen versus a shorter | | | | | | | | | | | | |
| | hydration protocol | | | | | | | | | | | | |
| 18/LO/1882 | 253030 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study | No | | 9 | | 04/05/20 | 18 03/04/201 | 9 13/02/2019 | 12/03/2019 | 12/04/2019 | 12/04/2019 | | |
| | of Abiraterone Acetate plus Prednisone with or without | | | | | | | | | | | | |
| | Abemaciclib in Patients with Metastatic Castration-Resistant | | | | | | | | | | | | |
| 18/LO/2023 | 253130 A double-blind, randomised, placebo controlled, adaptive design | Yes | 16/05/2019 | 0 | 36 | 36 13/11/20 | 18 10/04/201 | 9 18/01/2019 | 08/04/2019 | 10/04/2019 | 17/04/2019 | | |
| | study of the efficacy, safety and pharmacokinetics of NT-814 in | | | | | | | | | | | | |
| | female subjects with moderate to severe vasomotor symptoms | | | | | | | | | | | | |
| | associated with the menopause | | | | | | | | | | | | |
| 18/NE/0125 | 238346 A three-arm randomised controlled trial to assess the | No | | | | 12/04/20 | 18 17/06/201 | 9 | | | | | |
| | effectiveness and cost-effectiveness of reverse shoulder | | | | | | | | | | | | |
| | arthroplasty versus hemiarthroplasty versus non-surgical care for | | | | | | | | | | | | |
| | acute three and four- part fractures of the proximal humerus in | | | | | | | | | | | | |
| | patients over 65 years of age â€" Proximal Fracture Of the | | | | | | | | | | | | |
| | Humerus: Evaluation by Randomisation trial No.2 (PROFHER-2). | | | | | | | | | | | | |
| 18/NE/0214 | 245998 MN39158 - A Long Term Extension Study in Multiple Sclerosis | Yes | 19/10/2018 | 73 | 11 | 84 18/06/20 | 8 27/07/201 | 8 11/07/2018 | | 08/10/2018 | 10/10/2018 | D - Sponsor Delays | Sponsor |
| 18/NS/0093 | 237699 Assessment of the Impact of a Personalised Nutrition Intervention | | 26/11/2018 | 13 | 48 | | 18 26/09/201 | | | 09/10/2018 | 09/10/2018 | | эропзог |
| 10/143/0033 | in Impaired Glucose Regulation ASPIRE-DNA | 103 | 20,11,2010 | 13 | 40 | 01 1//0//20 | 20,03,201 | Ĭ | | 03/10/2010 | 03, 10, 2018 | Ί | |
| 18/NS/0100 | 236463 Hand Osteoarthritis: Investigating Pain Effects in a Randomised | No | + + | 110 | | 05/00/20 | 18 14/11/201 | 2 | | 04/03/2019 | 04/06/2019 | | - |
| 10/1/0/0100 | | INO | | 110 | | 05/09/20 | 14/11/201 | "[| | 04/03/2019 | 04/00/2019 | Ί | |
| | Placebo-Controlled Feasibility Study of Estrogen-Containing | | | | | | | | | | | | |
| 10/14/1/0276 | Therapy 24C112 Pandamicad Dauble Blind Blassha Controlled (within dose | No | + | 440 | | 02/02/22 | 10 02/00/201 | 0 20/40/2040 | 00/04/2044 | 20/01/2010 | 00/02/2010 | | |
| 18/WA/0276 | 246112 Randomised Double-Blind, Placebo-Controlled (within dose | No | | 149 | | 03/09/20 | 18 03/09/201 | 0 20/10/2018 | 09/01/2019 | 30/01/2019 | 08/02/2019 | Ί | |
| | groups) and Active Controlled (Eplerenone group) Trial to | | | | | | | 1 | | | | | |
| | Investigate the Safety, Tolerability, Pharmacokinetics and | | | | | | 1 | | | | | | |
| | Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in | | | | | | 1 | | | | | | |
| | Female and Male Patients with Diabetic Nephropathy | I | 1 1 | | I | ı | ı | 1 | 1 | 1 1 | ı | 1 | I |

| | | | | | | | | ı | | | | | |
|------------------|--|----------|--------------|-----|----|--|--------------|---------------|---------------|------------|------------|------------|---|
| 18/WA0385 | 254760 "A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b | No | | 201 | | | 21/11/2018 | 21/11/2018 | 5 | | 10/06/2019 | | |
| | Study of the Efficacy, Safety, and Tolerability of 6- Week Extended | | | | | | | | | | | | |
| | Interval Dosing of Natalizumab (BG00002) in Subjects With | | | | | | | | | | | | |
| | Relapsing-Remitting Multiple Sclerosis Switching From Treatment | | | | | | | | | | | | |
| | With 4-Week Natalizumab Standard Interval Dosing (SID) in | | | | | | | | | | | | |
| | Relation to Continued SID Treatment" | | | | | | | | | | | | |
| 18/WA/0417 | | No | | | | | 31/01/2019 | 15/04/2010 | 1 | 22/02/2019 | | | |
| 10/ 10/ 041/ | combination with paclitaxel and carboplatin in women with | | | | | | 31/01/2013 | 13/04/2013 | | 22/02/2013 | | | |
| | | | | | | | | | | | | | |
| 40/4/84/0006 | advanced/recurrent endometrial cancer" | NI- | | | | | 20/44/2047 | 4 4 /05 /2040 | 24/04/2040 | | | | |
| 18/WM/0006 | 225195 An Adaptive, Sequential Evaluation of Powered and Manual | No | | | | | 29/11/2017 | 14/05/2019 | 24/04/2019 | | | | |
| <u> </u> | Circular Staplers in Left-Sided Colorectal Anastomoses | | | | | | _ | | . | | | | |
| 18/WM/0199 | | No | | | | | 22/10/2018 | 10/05/2019 | 02/10/2018 | | | | |
| | Optimization: The HEMOTION TRIAL | | | | | | | | | | | | |
| 19/EE/0052 | 249678 A feasibility investigating different interventions for the treatment | No | | 21 | | | 15/01/2019 | 03/04/2019 | 03/04/2019 | 15/01/2019 | 24/04/2019 | | |
| | of benign paroxymsmal positional vertigo in acute traumatic brain | | | | | | | | | | | | |
| | injury patients | | | | | | | | | | | | |
| 19/EE/0185 | 260536 FIRST-line support for Assistance in Breathing in Children (FIRST- | No | | | | | 05/06/2019 | 18/06/2019 | | | | | |
| | ABC): A master protocol of two randomised trials to evaluate the | | | | | | 1 | | | | | | |
| | non-inferiority of high flow nasal cannula (HFNC) versus | | | | | | 1 | | | | | | |
| | continuous positive airway pressure (CPAP) for non-invasive | | | | | | 1 | | | | | | |
| | respiratory support in paediatric critical care | | | | | | | | | | | | |
| 19/E/0201 | 264655 "A Randomised, Single-blind, Placebo-controlled, Phase 1b Single | No | | | | | 22/03/2019 | 27/06/2010 | | | + | | + |
| 19/1/0201 | Ascending (Part A) and Multiple Dose (Part B) First-in-Man Study | INO I | | | | | 22/03/2019 | 27/00/2019 | | | | | |
| | | | | | | | | | | | | | |
| | in Adult Patients with Non-transfusion-Dependent Beta- | | | | | | | | | | | | |
| | Thalassaemia or Low Risk Myelodysplastic Syndrome to | | | | | | | | | | | | |
| | Investigate the Safety, Tolerability, Pharmacokinetic and | | | | | | | | | | | | |
| | Pharmacodynamic Response of SLN124" | | | | | | | | | | | | |
| 19/EM0020 | 252705 A phase II, open-label, prospective, single-arm, study to assess | No | | 33 | | | 29/03/2019 | 29/05/2019 | 23/05/2019 | | 01/07/2019 | | |
| | ability of eltrombopag to induce sustained remission in subjects | | | | | | | | | | | | |
| | with ITP who are refractory or relapsed after first-line steroids | | | | | | | | | | | | |
| | (TAPER) | | | | | | | | | | | | |
| 19/EM/0060 | 260387 A Phase 2, Randomized, Double-blind, Placebo-controlled Study of | No | | | | | 15/02/2019 | 28/06/2019 | 11/06/2019 | | | | |
| | Cemdisiran in Adult Patients with IgA Nephropathy | | | | | | ' ' | | | | | | |
| 19/EM/0063 | | No | | | | | 20/05/2019 | 17/06/2019 | 14/05/2019 | | | | |
| 23, 2, 3333 | Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in | | | | | | -0,00,-01 | 27,00,2020 | 1 ., 00, 2020 | | | | |
| | Subjects with Acute Myeloid Leukaemia (AML) or Myelodysplastic | | | | | | | | | | | | |
| | Syndromes (MDS) as Maintenance after Allogeneic | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| 10/10/0005 | Haematopoietic Stem Cell Transplantation. | | | | | | 22/44/2040 | 47/04/2040 | 25/04/2040 | 00/02/2040 | | | |
| 19/LO/0095 | 229300 Increase in colonic PRopionate as a method of prEVENTing weight | No | | | | | 23/11/2018 | 1//01/2019 | 25/01/2019 | 08/02/2019 | | | |
| | gain in young adults | | | | | | | | | | | | |
| 19/LO/0180 | 201748 A multicentre randomised controlled trial to assess the safety and | No | | | | | 18/12/2018 | 18/04/2019 | 17/04/2019 | 18/12/2018 | | | |
| | efficacy of adding rituximab to standard of care in treating acute | | | | | | | | | | | | |
| | antibody-mediated rejection in kidney transplantation (TAR:GET- | | | | | | | | | | | | |
| | 1) | | | | | | | | | | | | |
| 19/LO/0185 | 246354 Characterising the natural history of mucosal metabolism during | No | | | | | 20/12/2018 | 14/06/2019 | 25/02/2019 | | | | |
| | colorectal anastomotic healing | | | | | | | | | | | | |
| 19/LO/0196 | <u>~</u> | No | | | | <u> </u> | 04/08/2018 | 17/06/2019 | 18/04/2019 | | | | 1 |
| -,, | moderate to severe atopic eczema in children and adolescents-a | | | | | | , ==, ==== | , ::, =010 | .,, | | | | |
| | randomized placebo controlled phase 2 study | | | | | | 1 | | | | | | |
| 10/10/0262 | | Voc 1 | IE /0E /2010 | 0 | 10 | 20 | 0 02/10/2019 | 17/04/2010 | 10/02/2010 | 26/04/2010 | 26/04/2010 | 26/04/2010 | |
| 19/LO/0262 | 253945 Ripple Mapping Guided Early Ventricular Tachycardia Ablation: A | 1,62 | 15/05/2019 | 9 | 19 | 28 | 02/10/2018 | 1//04/2019 | 19/03/2019 | 20/04/2019 | 20/04/2019 | 26/04/2019 | |
| 40 / 0 / 2 : 2 2 | Multi-Centre Prospective Clinical Trial | <u>.</u> | 14/05/2215 | - | | <u> </u> | . | 47/04/22:5 | 1 | 40/04/2005 | 40/04/2212 | | + |
| 19/LO/0406 | • | Yes 1 | 14/05/2019 | 1 | 26 | 27 | ′ | 17/04/2019 | ' | 18/04/2019 | 18/04/2019 | | |
| | Allergy: A non-inferiority study | | | | | | <u> </u> | | | | | | |
| 19/LO/0836 | 262145 "INTERvention with Cerebral Embolic Protection in TEVAR | No | | | | | 22/02/2019 | 25/06/2019 | 07/06/2019 | | | | |
| | (InterCEPT): â€~Carbon-Dioxide Flushing versus Saline Flushing of | | | | | | 1 | | | | | | |
| | Thoracic Aortic Stents: A Multi-centre Randomised Controlled | | | | | | 1 | | | | | | |
| | Trial'" | | | | | | 1 | | | | | | |
| | | | | | | | | | | | | | |

| | | T | | | | 1 | I | l <i></i> | . T | 1 | | T | | |
|-----------------|---|------|--------------|-----|-----|-----|-------------|--------------|---|--------------|--|-------------|------------------------|---------|
| 19/NE/0077 | 258955 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, | No | | | | | 23/01/2019 | 17/04/2019 | 9 | | | | | |
| | Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular | | | | | | | | 1 | | | | | |
| | Lymphoma After Failure of Two or More Prior Systemic Therapies | | | | | | | | 1 | | | | | |
| 19/NW/0155 | 255226 A Phase 3, Open-Label, Randomized, Active-Controlled, | No | | 114 | | | 08/03/2019 | 09/03/2019 | 9 | | 01/07/2019 | | | |
| | Multicenter Study to Evaluate the Efficacy and Safety of | | | | | | | | 1 | | | | | |
| | Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in | | | | | | | | 1 | | | | | |
| | First-Line Treatment of Participants With Unresectable or | | | | | | | | 1 | | | | | |
| | Metastatic Cholangiocarcinoma With FGFR2 Rearrangeme | | | | | | | | | | | | | |
| 19/NW/0168 | 249133 A Phase II basket study of the oral selective pan-FGFR inhibitor | No | | | | | 12/03/2019 | 25/06/2019 | 9 | | | | | |
| | Debio 1347 in subjects with solid tumors harboring a fusion of | | | | | | | | 1 | | | | | |
| | FGFR1, FGFR2 or FGFR3 | | | | | | | | | | | | | |
| 19/NW/0174 | 261666 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- | No | | | | | 25/04/2019 | 21/05/2019 | 9 | | | | | |
| | Regional, International Study of Durvalumab in Combination with | | | | | | | | 1 | | | | | |
| | Gemcitabine plus Cisplatin versus Placebo in Combination with | | | | | | | | 1 | | | | | |
| | Gemcitabine plus Cisplatin for Patients with First-Line Advanced | | | | | | | | 1 | | | | | |
| | Biliary Tract Cancers | | | | | | | | 1 | | | | | |
| 19/SC/0031 | 257722 A randomised, placebo-controlled, double-blind, phase 1/2a study | No | | 24 | | | 18/12/2018 | 29/04/2019 |) | 23/05/2019 | 23/05/2019 | 23/05/2019 | | |
| | to evaluate the safety, reactogenicity, and immunogenicity of | | | | | | | | 1 | | | | | |
| | Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of | | | | | | | | 1 | | | | | |
| | age | | | | | | | | 1 | | | | | |
| 19/SC/0073 | | No | | | | | 17/04/2019 | 08/05/2019 | 02/05/2019 | | | | | |
| -,, | circular Frame external Fixation â€" A Feasibility study | | | | | | , , , , , , | | , , , , , | | | | | |
| 19/SS/0067 | 260522 The British Society of Endovascular Therapy ConformabLe | Yes | 26/06/2019 | 20 | 15 | 35 | 17/04/2019 | 22/05/2019 | 15/05/2019 | 22/05/2019 | 11/06/2019 | 11/06/2019 | | |
| | EndoVascular Aneurysm Repair Registry | | -5, 55, -5-5 | | | | , | ,, | ,, | ,, | | ,, | | |
| 19/SW/0078 | 253353 A pilot study to investigate the effect of phosphodiesterase | No | | 29 | | | 21/03/2019 | 23/05/2019 | 16/05/2019 | 23/05/2019 | 21/06/2019 | 24/06/2019 | | |
| 25,011,0070 | inhibitors on chorioretinal blood flow using optical coherence | | | | | | ,, | -5, 55, -5-5 | 1 20, 00, 2020 | -5, 55, -5-5 | | 2 1,00,2020 | | |
| | tomography angiography | | | | | | | | 1 | | | | | |
| 19/WA/0010 | 233295 "TALAPRO-2 A Phase 3, Randomized, Double-Blind, Placebo- | No | 1 | | | | 28/02/2018 | 24/04/2019 | 22/05/2019 | | | | | + |
| 13, 17, 1, 0010 | Controlled Study of Talazoparib with Enzalutamide in Metastatic | | | | | | 20,02,2010 | 2-1,0-1,2013 | , | | | | | |
| | Castration-Resistant Prostate Cancer" | | | | | | | | 1 | | | | | |
| 19/YH/0013 | 255993 A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) | No | | | | | 19/11/2018 | 20/06/2019 | 1 | | | | | |
| 13/111/0013 | in Combination with Atezolizumab versus Sorafenib in Subjects | 140 | | | | | 13/11/2010 | 20,00,2013 | Ί | | | | | |
| | with Advanced Hepatocellular Carcinoma Who have not received | | | | | | | | 1 | | | | | |
| | · | | | | | | | | 1 | | | | | |
| 10 //11/0054 | Previous Systemic Anticancer therapy. 258802 A pragmatic, multicentre, randomised controlled trial to assess | Vos | 26/06/2010 | | | 27 | 07/02/2010 | 20/05/2010 | 05/04/2010 | | | | | + |
| 19/YH/0054 | the clinical and cost effectiveness of negative pressure wound | Yes | 26/06/2019 | | | 3/ | 07/02/2019 | 20/05/2019 | 05/04/2019 | | | | | |
| | • • • | | | | | | | | 1 | | | | | |
| | therapy versus usual care for surgical wounds healing by | | | | | | | | 1 | | | | | |
| 10/11/1/0077 | secondary intention (SWHSI-2) | NI - | + | | | | 42/02/2040 | 42/06/2040 | | 42/02/2040 | 47/06/2040 | | | _ |
| 19/WA/0077 | 256787 Optimal Vascular Access for Elderly Haemodialysis Patients: a | No | | 4 | | | 12/02/2019 | 13/06/2019 | " | 12/02/2019 | 17/06/2019 | | | |
| | randomised controlled study comparing tunnelled haemodialysis | | | | | | | | 1 | | | | | |
| 10/51/0011 | catheters and native arteriovenous fistulae | | 1 | | | | 20/20/20/2 | 10/11/0010 | 0.11.120.10 | | 24/12/2212 | | | |
| 18/EM/0244 | , , , , , , | No | | 35 | | | 28/08/2018 | 16/11/2018 | 01/11/2018 | | 21/12/2018 | | | |
| 40 /2004 /2= 2= | (HIFU) in late stage pelvic cancer | ļ | 4 | | | | 04/05/55:5 | 10/05/55: | 0.4.10 - 15 - 1 - | | | | | |
| 18/NW/0765 | 250220 Validating a Device for the Detection of Bacteria and Leukocytes in | No | | | | | 21/08/2018 | 10/05/2019 | 01/04/2019 | | | | | |
| | Peritoneal Effluent from Patients with Suspected Peritonitis | | | | | | | 22/11/ | 1 1 1 | | | | | |
| 18/SC/0240 | 230920 A Phase III, Multicenter, Randomized, Double-Blind, Placebo- | Yes | 26/03/2019 | 19 | 104 | 123 | 12/03/2018 | 23/11/2018 | 07/06/2018 | 05/12/2018 | 12/12/2018 | | F - No patients seen | Neither |
| | Controlled, Parallel-Group, Efficacy, and Safety Study of | | | | | | | | | | | | | |
| | Gantenerumab in Patients with Early (Prodromal to Mild) | | | | | | | | 1 | | | | | |
| | Alzheimer's Disease | | | | | | | | <u> </u> | | | | | |
| | | | | | | | | | 1 | | | | H - Contracting delays | |
| 19/LO/0074 | · | No | | | | | 24/09/2018 | 09/04/2019 | 19/03/2019 | | | | | |
| | to Assess the Efficacy and Safety of Orally Administered DS102 in | | | | | | | | | | | | | |
| | Patients with Severe Acute Decompensated Alcoholic Hepatitis | | | | | | | | | | | | | |